Figure 1.
Patient disposition. The percentage of patients completing or not completing treatment periods is calculated with the initial number of patients who were randomised to that group. Completed not on randomised treatment refers to patients that stopped treatment but continued in the study. ADA, adalimumab; BKZ, bimekizumab; Q2W, every 2 weeks; Q4W, every 4 weeks.